AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
InMode Lowers Revenue Forecast Amid Market Challenges, GuruFocus Sees Significant Upside
ByAinvest
Sunday, Jul 13, 2025 1:37 am ET1min read
InMode (INMD) lowers Q2 2025 revenue forecast to $95.4-95.5mln, missing consensus estimate of $98.45mln. The company adjusts its full-year 2025 revenue projection to $365-375mln, down from $395-405mln. Wall Street analysts hold a mixed outlook with a "Hold" recommendation and varied price targets. GuruFocus estimates a significant upside of 55.41% based on GF Value assessment.
InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, has announced revised revenue forecasts for the second quarter of 2025. The company expects revenue to range between $95.4 million and $95.5 million, a significant drop from the previously projected $98.45 million, according to consensus estimates [2].The adjustment in revenue projections reflects the ongoing economic uncertainty and market weakness, which have led to a downward revision in InMode's full-year 2025 revenue guidance. The company now anticipates full-year revenue to be in the range of $365 million to $375 million, down from the prior guidance of $395 million to $405 million [1].
InMode will host a conference call on Wednesday, July 30, 2025, at 8:30 a.m. Eastern Time, to discuss the second quarter 2025 financial results. The call will feature Moshe Mizrahy, Chief Executive Officer, Yair Malca, Chief Financial Officer, and Dr. Michael Kreindel, Chief Technology Officer [1].
The stock market's response to InMode's revised guidance has been mixed, with analysts providing a "Hold" recommendation and varied price targets. GuruFocus estimates a significant upside of 55.41% based on its GF Value assessment [3].
References:
[1] https://finance.yahoo.com/news/inmode-report-second-quarter-2025-110000156.html
[2] https://www.marketscreener.com/quote/stock/INMODE-LTD-63383136/news/Inmode-Ltd-Provides-Revenue-Guidance-for-the-Second-Quarter-of-2025-50479453/
[3] https://simplywall.st/stocks/us/healthcare/nasdaq-inmd/inmode/future
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet